FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	
------------------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

3235-0287 OMB Number:

Estimated average burden hours per response: 0.5

OMB APPROVAL

Ch	eck this box if no longer subject to
Se	ction 16. Form 4 or Form 5
ob	ligations may continue. See
Ins	struction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Crowley Elizabeth						2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]									k all appli Directo	or		10% Ov	vner
	(Last) (First) (Middle) C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220							est Trar	(Mont	th/Day/Year)		X	X Officer (give title below) Other (specify below) Sr. VP &CPDO						
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)									ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S	tate)	(Zip)			Pers									Persor	1			
		Tab	le I - N	lon-Deriv	ative	Sec	urit	ies Ad	quire	d, Di	isposed o	of, or Be	enefic	ially	Owned	i			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/N						Exec if any	Deemed cution Date, y nth/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			nd 5) Securiti Benefic Owned		es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership
					Code	v	Amount	(A) or (D)	Price			rted action(s) . 3 and 4)			(Instr. 4)				
Common	2021	21			М		4,000(1)	A	\$9.01	.65(1)	8,726			D					
Common Stock 12/08/20.					2021)21			S ⁽²⁾ 4,		4,000(2)	D	\$4	0 4		4,726		D	
		Т	able II								posed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)) if any	emed ion Date, /Day/Year)	4. Transa Code (8)				6. Date Exerci Expiration Dat (Month/Day/Ye		ate	7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		D Si (li	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er					
Incentive Stock Option (Right to	\$9.0165 ⁽¹⁾	12/08/2021			M			4,000	(3)		06/13/2028	Common Stock	4,00	0	\$0.00	16,000 ⁽	1)	D	

Explanation of Responses:

- 1. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of \$0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
- 2. The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.
- 3.25% vested on June 13,2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

/s/ Samuel Martin, attorney in fact for Elizabeth Crowley

** Signature of Reporting Person

12/10/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.